Impact of Antiretroviral Therapy on the Risk of Recurrence in HIV-1 Infected Patients with Kaposi Sarcoma: A Multicenter Cohort Experience

Autor:	Manuela Colafigli, Sara Modica, Simona Di Giambenedetto, Ilaria Uccella, Virginia Ferraresi, Barbara Rossetti, Roberto Cauda, Arturo Ciccullo, Iuri Fanti, Alessandra Latini, Alberto Borghetti, Enza Anzalone, Emilia Migliano, Antonio Bonadies, Giordano Madeddu, Alfredo Pennica, Federico Melis, Antonio Cristaudo
Jazyk:	angličtina
Rok vydání:	2019
Předmět:	medicine.medical_specialty medicine.medical_treatment Integrase inhibitor Malignancy Settore MED/17 - MALATTIE INFETTIVE Article 03 medical and health sciences 0302 clinical medicine Internal medicine medicine 030212 general & internal medicine acquired immunodeficiency syndrome (AIDS) 0303 health sciences Chemotherapy Reverse-transcriptase inhibitor 030306 microbiology business.industry Incidence (epidemiology) HIV infection Kaposi sarcoma virus diseases General Medicine medicine.disease Regimen Cohort Sarcoma business medicine.drug
Zdroj:	Journal of Clinical Medicine Volume 8 Issue 12
ISSN:	2077-0383
DOI:	10.3390/jcm8122062
Popis:	Kaposi sarcoma (KS) remains a relevant malignancy in human immunodeficiency virus (HIV)-infected patients with a non-standardized management despite past suggestions that ritonavir-boosted protease inhibitor (bPI)-based regimens could be preferable, no combination antiretroviral therapy (cART) regimen was demonstrated to outperform the others and the impact of new drugs, drug classes or paradigms was never investigated nor proven better than previous therapeutic regimes. In order to do this, we retrospectively collected data regarding HIV-infected patients with a diagnosis of KS last seen in six Italian centers after 1 January 2013. A total of 104 KS cases in 99 patients was analyzed for 945.34 patient-year follow-up (PYFU). Twenty-six patients had visceral localizations. Thirty-three patients were treated with chemotherapy, four with electrochemotherapy, and 12 with &alpha interferon (&alpha IFN). At censor, 22% received a bPI-based, 14% a non-nucleoside reverse transcriptase inhibitor (NNRTI)-based, and 28% an integrase inhibitor (INI)-based standard cART, 24% a less drug regimen and 12% a mega-cART. Twelve recurrence episodes were observed in seven patients for an incidence of 1.27 per 100 PYFU. Two patients with no evidence of recurrence episodes died for other reasons. In our experience, KS recurrence episodes were infrequent. Despite the increasing use of new antiretroviral drug classes and new treatment paradigms, no excess of recurrence episodes was observed in patients receiving such cART regimens.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c1ab3fc6e590592b5df200074b46337 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.